Macrogen

10x Genomics Launches Xenium Catalyst Network

Retrieved on: 
Mercoledì, Dicembre 20, 2023
Biology, Contract research organization, Partnership, Drug discovery, Medicine, Collection, Business, Research, 10x Genomics, Tissue, McDonnell Genome Institute, Sundaram, Cancer, Genomics, K2, Macrogen

PLEASANTON, Calif., Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc., (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide. The four founding members of the Xenium Catalyst Network will add significant capacity for the company's Xenium Catalyst Program, a technical access service launched earlier this year for prospective customers.

Key Points: 
  • The four founding members of the Xenium Catalyst Network will add significant capacity for the company's Xenium Catalyst Program, a technical access service launched earlier this year for prospective customers.
  • 10x Genomics expects to add more research institutions to the Xenium Catalyst Network in 2024.
  • "K2bio, a novel full service preclinical Contract Research Organization (CRO), welcomes our partnership with 10x Genomics and the Xenium Catalyst Network," said Kieron Jones, CEO at K2bio.
  • "Participating in the 10x Genomics Xenium Catalyst Network will help us deliver state-of-the-art spatial genomics services," stated Michael Heinz, Director of Research Operations at the McDonnell Genome Institute.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Lunedì, Novembre 6, 2023
Research, Sale, IND, Half-life, Acute myeloid leukemia, Enoblituzumab, Bispecific monoclonal antibody, Food, Therapy, RPF, Telephone, Docetaxel, Macrogen, B7, HEAT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prostate cancer, Gilead Sciences, CD123, Syndrome, ADC, ID, Webcast, Cancer, Conference call, Patient, Cytokine release syndrome, Monoclonal antibody, D, Fine chemical, Pharmaceutical industry, Vaccine, Conference

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.
  • Revenue: Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.
  • R&D Expenses: Research and development expenses were $30.1 million for the quarter ended September 30, 2023, compared to $48.2 million for the quarter ended September 30, 2022.
  • SG&A Expenses: Selling, general and administrative expenses were $12.4 million for the quarter ended September 30, 2023, compared to $15.4 million for the quarter ended September 30, 2022.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Giovedì, Novembre 2, 2023
Macrogen, Cancer, Therapy, Webcast, Fine chemical, Online shopping, Pharmaceutical industry, MD

ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:

Key Points: 
  • ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:
    Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.
  • The Company will maintain archived replays of these webcasts on its website for 30 days.

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call

Retrieved on: 
Martedì, Ottobre 31, 2023
Macrogen, Telephone, Cancer, ID, Webcast, Therapy, Pharmaceutical industry, Internet service provider, Security (finance), MD

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023.

Key Points: 
  • ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023.
  • MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, November 6, 2023, at 4:30 pm ET.
  • To participate via telephone, please register in advance at this link .
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

Retrieved on: 
Giovedì, Ottobre 19, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Illinois College, MedImmune, NCI, Molecular biology, AstraZeneca, Beth Israel Deaconess Medical Center, Senior, Macrogen, Princeton University, University, Internal medicine, National Cancer Institute, Carcinoma, Beth, Patient, Human Genome Sciences, Nursing, Immunome, Seagen

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.
  • Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.
  • “We are delighted to welcome Bob to our team during an exciting time in Immunome’s growth as we focus on advancing our oncology pipeline into the clinic,” said Dr. Siegall, President and Chief Executive Officer of Immunome.
  • I would like to extend my thanks to Dr. Siegall and the entire Immunome team for welcoming me to the company,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.

NanoString Expands Partnerships with Contract Research Organizations Making Spatial Molecular Imaging Tools Widely Available to Global BioPharma Researchers

Retrieved on: 
Giovedì, Settembre 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Genetics, Partnership, DSP, SMI, GCP, MicroRNA, Gene expression, RNA, Proteomics, Protein, Patient, Contract research organization, NanoString Technologies, Biology, Ecosystem, Gene, ChromeOS, Fine chemical, Macrogen

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, announced today three new Contract Research Organization (CRO) CosMxTM Spatial Molecular Imager partnerships.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, announced today three new Contract Research Organization (CRO) CosMxTM Spatial Molecular Imager partnerships.
  • Macrogen, Propath UK, and Sirona Dx offer global biopharma customers new access to CosMx™ SMI technology for translational drug development.
  • “NanoString is honored to partner with these leading CROs and accelerate access to spatial biology capabilities for biopharma companies around the world,” stated Brad Gray, President and CEO of NanoString.
  • The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

Retrieved on: 
Martedì, Settembre 5, 2023
Bispecific monoclonal antibody, Monoclonal antibody, Gilead Sciences, Therapy, CD3, Cancer, Macrogen, Research, Gilead, GILD, CD123, Pharmaceutical industry, MD

This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.

Key Points: 
  • This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.
  • Under the October 2022 agreement, MacroGenics will receive $15 million related to the nomination of a bispecific research program to be conducted by MacroGenics and funded by Gilead.
  • Pursuant to this agreement, which covers MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and up to two additional bispecific research programs, MacroGenics remains eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones.
  • MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Giovedì, Agosto 31, 2023
Cancer, Macrogen, Therapy, Conference, MD

Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Discussion on Wednesday, September 6, 2023, at 10:30 am ET.

Key Points: 
  • Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Discussion on Wednesday, September 6, 2023, at 10:30 am ET.
  • MacroGenics’ management will also participate in one-on-one meetings.
  • MacroGenics’ management will also participate in one-on-one meetings.
  • Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

Retrieved on: 
Mercoledì, Agosto 9, 2023
Docetaxel, PROTECT, ASC, B7-H3, Therapy, Half-life, Conference call, Bank statement, Telephone, Cancer, Macrogen, GAAP, RPF, ID, Sale, Acute myeloid leukemia, ASCO, B7, Patient, DRI, Syndrome, CD123, Webcast, ADC, Cytokine release syndrome, Enoblituzumab, Research, FDA, IND, Economics, Prostate cancer, D, Fine chemical, Pharmaceutical industry, Vaccine, Security (finance), Sanofi, Conference

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2023.
  • MacroGenics began enrolling the TAMARACK Phase 2 study of vobra duo in patients with mCRPC under an amended protocol during the second quarter.
  • MacroGenics anticipates enrolling a majority of the study patients in 2023 and expects to provide a clinical update in 2024.
  • R&D Expenses: Research and development expenses were $43.2 million for the quarter ended June 30, 2023, compared to $51.7 million for the quarter ended June 30, 2022.

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

Retrieved on: 
Lunedì, Luglio 31, 2023
Telephone, Webcast, ID, Cancer, Macrogen, Therapy, Rare-earth element, Internet service provider, MD

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes on Wednesday, August 9, 2023.

Key Points: 
  • ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes on Wednesday, August 9, 2023.
  • MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, August 9, 2023, at 4:30 pm ET.
  • To participate via telephone, please register in advance via this link .
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .